TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01841892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Therapeutic Workplace
Description: Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
Study: NCT03941002

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Assesment of diaphragm function
Description: Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assesment of diaphragm function
Description: Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assesment of diaphragm function
Description: Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
Study: NCT04356456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumenato
Description: tomato oleoresin obtained from yellow dry tomato pulp

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lumenato
Description: tomato oleoresin obtained from yellow dry tomato pulp
Study: NCT02139150

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F] FLT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scans
Study: NCT00140855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study: NCT03700099

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
Study: NCT03707912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaferon
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT04357639

Intervention type: OTHER
Intervention: No intervention
Description: No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection

Intervention type: OTHER
Intervention: No intervention
Description: No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection
Study: NCT03222817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Description: Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
Study: NCT03087747

Intervention type: PROCEDURE
Intervention: Percutaneous cholecystostomy
Description: Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.

Intervention type: PROCEDURE
Intervention: Percutaneous cholecystostomy
Description: Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
Study: NCT00651820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Santyl
Description: Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Collagenase Santyl Vehicle
Description: Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
Study: NCT03847441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol ointment (0.005%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol ointment (0.005%)
Study: NCT01804777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet
Study: NCT01460147

Intervention type: OTHER
Group type: OTHER
Intervention: DXA scan + MRI
Description: This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
Study: NCT03735251

Intervention type: OTHER
Intervention: Diuretic，Betaloc，antiplatelet drugs
Description: According to international guidelines,we treated patinets who suffered from different disease
Study: NCT06016894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: coronally advanced flap operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: coronally advanced flap operation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystalline hydroxyapatite loaded in PRF
Description: Nanocrystalline hydroxyapatite loaded in PRF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystalline tricalcium phosphate loaded in PRF
Description: Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF
Study: NCT03497247

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive-Behavioral Therapy
Description: Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive-Behavioral Therapy
Description: Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
Study: NCT03847441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narrow Band UVB
Description: NB-UVB (311nm) phototherapy
Study: NCT03921294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: bispecific monoclonal antibody binding to activated Factor IX and Factor X
Study: NCT00831428

Intervention type: OTHER
Intervention: no intervention
Description: this is a screening study, not an interventional study
Study: NCT00524264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ketorolac
Description: Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo
Study: NCT01161615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-7EAT
Description: Application of up to two patches for up to 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of up to two patches for up to 7 days.
Study: NCT00709566

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise and manual therapy
Description: Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
Study: NCT04336696

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy and central neck dissection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total thyroidectomy and central neck dissection
Study: NCT02066207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Study: NCT03847441

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 level
Description: vitamin D3 (ng/ml)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 level
Description: vitamin D3 (ng/ml)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 level
Description: vitamin D3 (ng/ml)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3 level
Description: vitamin D3 (ng/ml)
Study: NCT03680235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive standard information about breastfeeding and pregnancy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive standard information about breastfeeding and pregnancy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information about breastfeeding and cancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in focus groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in focus groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02066207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT01579357

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min
Study: NCT01860105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDCO-157
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDCO-157
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDCO-157
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLAVIX
Description: oral administration
Study: NCT00381225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra-sound guided radio-frequency ablation
Study: NCT02864615

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Dose and schedule will be depended on metastases location.
Study: NCT02276339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
Study: NCT01532674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (Periowave) and scaling and root planing
Description: ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~* Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~* Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~* All the periodontal pockets will be treated subgingivally~* Elimination of the photosensitive by irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~\* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque.
Study: NCT03639662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sophrology sessions
Description: Patients benefit from additional support consisting of at least 3 sessions of sophrology, one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for irathérapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions
Study: NCT03878719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally
Study: NCT02188953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACCS100
Description: ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate placebo
Study: NCT00890422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME vaccination (FSME-Immun)
Description: intra muscular 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME vaccination (FSME-Immun)
Description: intra muscular 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME vaccination (FSME-Immun)
Description: intra muscular 0.5 ml
Study: NCT04138147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial cervical plexus with auriculotemporal nerve blocks
Description: Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical retrolaminar with auriculotemporal nerve blocks
Description: Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
Study: NCT03214822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: H2MF
Description: As described in the Experimental Arm description.
Study: NCT03680235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04109417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteotomy filled with PRP-gel and covered with PRP-biomembrane

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: osteotomy site following the surgical intervention was left empty
Study: NCT00392847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promoting Parental Skills and Enhancing Attachment
Description: The first group will receive routine follow-up as currently provided by national community health and social services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: had home visits by community workers during pregnancy
Description: had home visits by community workers during pregnancy to the child's second birthday.
Study: NCT04133623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
Study: NCT01762618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Group
Description: Therapy Groups
Study: NCT01134848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 10mg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 1mg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: 0.1 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: 1 unit/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: 1ml IM
Study: NCT01305226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-100
Description: THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
Study: NCT03991260

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT
Description: One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT
Description: One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
Study: NCT01846923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Study: NCT02215161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT00736970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
Study: NCT05088005

Intervention type: PROCEDURE
Intervention: Hyperbaric oxygen therapy
Description: Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
Study: NCT00883688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Pills of 700 mg/m\^2/dose given orally 2 times each day.
Study: NCT04610957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosafem (FEMININE FORMULA)
Description: Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
Study: NCT05599074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extrusion arch
Description: A stainless steel pre-formed arch wire custom made by placing V-bends 3-5 mm mesial to the molar tubes, placed into the auxiliary molar tubes after leveling phase and tied over the main arch wire distal to the lateral incisors
Study: NCT03918486

Intervention type: DEVICE
Intervention: Caretaker
Description: Application of Caretaker device to subjects that are scheduled for elective surgeries.
Study: NCT01259583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2
Description: CO2 insufflation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm water
Description: warm water irrigation
Study: NCT02605148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: Gluten free diet during 18 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega 3 fatty acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Omega 3 fatty acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 800 U/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 800 U/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics
Study: NCT06486129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation volume targetted
Description: he aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (BiPAP) on cardiac parameters and myocardial biomarkers in patients with OHS
Study: NCT01346007

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming